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Background: Lung cancer patients with mutations in the epidermal growth factor receptor (EGFR) are primary
candidates for EGFR-targeted therapy. Reliable analyses of such mutations have previously been possible only in
tumour tissue. Here, we demonstrate that mutations can be detected in plasma samples with allele-specific PCR assays.
Methods: Pairs of the diagnostic biopsy and plasma obtained just prior to start of erlotinib treatment were collected
from 199 patients with adenocarcinoma of non-small-cell lung cancer. DNA from both sample types was isolated and
examined for the presence of mutations in exons 18–21 of the EGFR gene, employing the cobas® EGFR Tissue Test and
cobas® EGFR Blood Test (in development, Roche Molecular Systems, Inc., CA, USA).
Results: Test results were obtained in all 199 (100%) plasma samples and 196/199 (98%) of the biopsies.
EGFR-activating mutations were identified in 24/199 (12%) plasma samples and 28/196 (14%) biopsy samples,
and 17/196 (9%) matched pairs contained the same mutation. Six EGFR mutations were present only in plasma
samples but not in the biopsy samples. The overall concordance of the EGFR gene mutations detected in plasma
and biopsy tissue was 179/196 (91%) (kappa value: 0.621).
Conclusion: Mutational analysis of the EGFR gene in plasma samples is feasible with allele-specific PCR assays
and represents a non-invasive supplement to biopsy analysis.
Trial registration: M-20080012 from March 10, 2008 and reported to ClinicalTrials.gov: NCT00815971.
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Activating mutations in the tyrosine kinase domain of
the EGFR gene in tumour tissue predict clinical response
of advanced non-small-cell lung cancer (NSCLC) to
tyrosine kinase inhibitors (TKI’s) such as gefitinib and
erlotinib [1-4]. However, obtaining adequate tumour
tissue from patients with NSCLC for molecular analysis
can be challenging. First, the biopsies are often small,
and the number of tumour cells retrieved may be too
low to allow such analysis. Second, the biopsy may not
be representative of the total burden of mutated cells,
especially in patients with metastases. A third problem* Correspondence: boesoere@rm.dk
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reproduction in any medium, provided the oris that genetic changes may take place during the interval
between removal of the biopsy and start of TKI treatment,
especially in patients receiving chemotherapy or radiother-
apy [5]. Previous reports showed that EGFR mutations
can be detected in patient’s serum or plasma [6-11], but
the success rates for detecting EGFR in blood appear to
vary according to the technology used [7-12].
The cobas® EGFR Tissue and Blood tests are allele-
specific PCR assays designed to detect EGFR gene
mutations in exons 18–21. Here, we evaluated these
allele-specific PCR assays’ ability to detect EGFR muta-
tions in plasma samples removed just prior to start of
treatment with erlotinib, as compared to the results
obtained for the diagnostic biopsy.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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Patients
A cohort of 199 patients with advanced adenocarcinoma
(or mixed tumours with an adenocarcinoma component)
treated at the Department of Oncology, University Hospital
of Aarhus, from October 2008 to October 2011, were
used for the study. During 2008–2011, the standard
treatment for all patients with adenocarcinoma of the
lung was carboplatine (AUC 5) i.v. and oral vinorelbine
60–80 mg/kg as first line and erlotinib as second line
(Table 1). Archived plasma samples from blood taken
prior to erlotinib treatment (within 2 days) were used for
EGFR testing, and the diagnostic biopsies were retrieved
for tissue testing. Only 196 diagnostic biopsy samples were
tested because no tumour cells could be identified inTable 1 Patients and tumour characteristics for 199 lung









Current smoker 64 32
Former smoker 118 59








Adenosquamous carcinoma 9 5
Tumour stage
IIA + IIB 2 1







Age (years, mean (range)) 64 (33–87)
*Eastern Cooperative Oncology Group scale to assess how the disease affects
the daily living abilities of the patient.two biopsy samples, and one biopsy did not contain a
sufficient quality of DNA for the mutation analysis.
Patient characteristics were obtained for all 199 patients
(Table 1).
Trial registration
The project was approved by the Central Denmark Region
Committees on Biomedical Research Ethics (M-20080012)
and reported to ClinicalTrials.gov (NCT00815971). Writ-
ten informed consent for participation in the study was
obtained from all participants.
Tumour and plasma samples
In all, 197 of 199 patients had tumour cells in the diagnos-
tic biopsy (99%). In 92 of 197 patients (47%), the diagnostic
tissue was from a fine-needle aspiration biopsy (cytology),
whereas in the other 105 patients (53%), the diagnostic
tissue consisted of formalin-fixed paraffin-embedded tissue
from a gross-needle biopsy or from a surgical specimen.
All samples were re-evaluated by the same pathologist to
confirm the original diagnosis and classified using the 2004
World Health Organisation (WHO) classification. If more
than one block or several smears were available from the
same biopsy, the one that contained the highest number of
tumour cells was used for testing. The pathologist evaluated
the percentage of tumour cells. The tumour cell content
was below 30% in most samples (64.5%) and below 10%
in 12.7% of the samples. Most biopsies (102) were from
the primary tumour, but for 22 and 75 patients, mutation
detection was performed on biopsies from lymph node
metastasis or distant metastasis, respectively. Blood samples
were collected in collection tubes (©Terumo, Europe NV)
containing EDTA prior to the erlotinib treatment (within
2 days). Centrifugation was performed at 1000 rpm for
15 min, and plasma was removed and stored at −80°C.
The plasma samples were collected at a median of
10.5 months after the diagnostic biopsy had been taken,
and our results are therefore not a direct comparison of
the presence of mutated EGFR in biopsies and plasma
collected at the same time.
DNA extraction from paraffin-embedded tissue sections
Five slices were cut from the paraffin-embedded blocks.
The two outermost sections were stained with haema-
toxylin/eosin. If tumour cells could be identified in both
sections, the three middle slices were used for DNA
extraction. Sections were deparaffinised by submersion in
xylene and rehydrated with ethanol. DNA was extracted
using the QIAamp DNA FFPE Tissue Kit (Qiagen,
Germany) according to the manufacturer’s protocol.
DNA extraction from archived cytological slides
Manual macro-dissection was performed in 4% of the
samples when the tumour cells were clustered in small
Table 2 EGFR mutations in paired samples of plasma DNA
and biopsy samples (n = 199)
Plasma DNA
Biopsy DNA Mutated Wild-type Total
Mutated 17 11 28
Wild-type 6 162 168
Not classified 1 2 3
Total 24 175 199
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slide surface. In the remaining 96% of the samples, all of
the cells were taken. The slides were rinsed in 96% etha-
nol. PBS (phosphate buffered saline) was added on the
smear surface before the cells were gently scraped from
the slide. DNA was extracted using the QIAamp DNA
Mini Kit (Qiagen, Germany) according to the manufac-
turer’s protocol. The resulting DNA was measured with a
Nanodrop UV–vis Spectrophotometer and then diluted
with DNA SD (sample diluent) to 2 ng/μL concentration.
DNA extraction from plasma
For each testing 2 mL of the plasma was used. In the
cobas® DNA Sample Preparation kit, Proteinase K, WBI
(wash buffer I) and WBI (wash buffer II) were prepared
according to the manufacturer’s instructions. The plasma
was mixed with 250 μL Proteinase K and 2 mL DNA PBB
(binding buffer) and incubated at room temperature for
30 minutes. Then 500 μL isopropanol was mixed with
the lysate and transferred into the High Pure Extender
Assembly. The High Pure Extender Assemblies were
centrifuged at 4000 × g for 1 min. The extenders were
removed from the filters; the filters were placed in new
collection tubes and washed with WBI and WBII
according the manufacturer’s instructions. The DNA
was eluted in 100 μL DNA EB (elution buffer).
Mutation analysis
The cobas® EGFR Tissue Test was used for mutation
detection. The test is designed to detect G719A/C/S in
exon 18; 29 deletions in exon 19; S768I, T790M and 5
insertions in exon 20; and L858R in exon 21. In
addition to mutations detected in the tissue test, the
cobas EGFR Blood Test also detects L861Q in exon 21.
For the FFPET samples, 50 ng genomic DNA was used
for each PCR reaction, and for the plasma samples,
25 μL of the DNA eluate was used for each PCR reaction.
The cobas® 4800 SR2 System Software v2.0 and EGFR
Analysis Package Software v1.0 were used for tissue
analysis. For the blood testing, the EGFR Blood Ana-
lysis Package Software (in development) was used. The
cobas® EGFR tissue and blood tests were provided by
Roche Molecular Systems, Inc. free of charge as the
result of research collaboration.
Statistical analysis
False-positive and false-negative rates could not be
determined, as no reference or gold standard has been
defined for EGFR mutation analysis. To test the difference
between paired samples (biopsy and plasma), McNemar’s
test was used. The difference was considered statistically
significant when p < 0.05. The statistical software SPSS
(18) for Windows; SPSS Inc., Chicago, IL, USA) was used
for the calculations.Results
The EGFR mutation status was determined in all plasma
samples (199/199), giving a success rate of 100%. In the
199 biopsy samples from the same patients, the success
rate was 98% (196/199). One tissue sample did not contain
sufficient DNA, and other two tissue samples did not
contain any tumour cells. Interestingly, in one of these
three patients, an L858R mutation was found in the
plasma DNA. Among 199 advanced adenocarcinoma
patients, 24/199 (12%) were EGFR-mutation positive in
plasma and 28/196 (14%) were EGFR-mutation positive
in tumour DNA.
A comparison of EGFR mutations in plasma and tumour
DNA is shown in Table 2. The overall concordance of
EGFR mutation status in plasma and tumour biopsy was
91% (179/196). In all, 17/196 (9%) patients had the same
EGFR mutations in plasma as in their original diagnostic
biopsy, and 162/196 (82%) patients remained mutation
negative. There was no statistically significant differ-
ence between the frequency of samples with mutations
detected in plasma and biopsy DNA (p = 0.332) as tested
by McNemar’s test. In this study, a difference in EGFR
mutation status in plasma and original biopsy was observed
in 17 of 196 (9%) patients. Of the 23 patients that were
EGFR-mutation positive in plasma DNA, 6 were positive
in the plasma only, and of the 28 patients that were EGFR
mutation positive in tumour DNA, 11 were mutation
positive in the tumour only. These differences could
reflect the limitation of assay technology with circulating
cell-free DNA in the plasma, tumour heterogeneity, and/
or the effect of chemotherapy.
Deletions in exon 19 were the most common mutation
and were found in 75% and 82% of all mutations in the
biopsy and plasma samples, respectively. Point mutations
in exon 21 (L858R) represented 21% and 18% of the
mutations found in tumour tissue and plasma samples,
respectively. A single exon 20 insertion was found in a
biopsy sample, but none were observed in plasma DNA.
We found the same mutation rate in cytology and hist-
ology specimens (15% vs. 14%), supporting the notion
that both specimens are suitable for DNA extraction and
EGFR mutation analysis. For the patients with mutations
in the blood but not in the biopsy, the tumour cell count
in the biopsy was similar to that in the rest of the
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fraction of cytology samples was 50% (three cytology and
three histology samples) and resembled the rest of the
tumour samples in the study.
Patients with activating EGFR mutations in plasma DNA
had a longer progression-free survival than patients without
these mutations (p = 0.01) as illustrated in Figure 1. Median
progression-free survival was 5.7 months in the patients
with EGFR mutations versus 2.8 months in the patients
without these mutations.
Discussion
In this study, we show that it is feasible to detect EGFR
mutations in plasma from patients with advanced lung
cancer. Among 199 patients, there were 24 that carried
EGFR mutations that could be identified in plasma samples
taken just prior to start of treatment with the EGFR-
directed drug erlotinib.
The primary objective of this study was to explore the
use of a newly developed method for identification of
EGFR mutations in plasma. In addition, we compared
the mutation status in plasma to the mutation status in
the original diagnosis biopsy from the same patients.
Plasma samples were collected at a median of 10.5 months
after the biopsy was obtained. Thus our results do not
represent a direct comparison of the presence of mutated
EGFR in biopsies and plasma collected at the same time.Figure 1 Kaplan-Meyer curve showing progression-free survival (PFS)
EGFR mutations identified in the plasma DNA. The group with activatin
without these mutations, with a p-value of 0.01.Despite this, several interesting findings were observed.
First, the allele-specific PCR assay is robust and produced
test results for 100% of the plasma samples. Second, for
17 patients whose EGFR mutations were detected in both
the diagnostic biopsy and the plasma sample identical
mutations were found in both the diagnostic biopsy and
plasma sample collected prior to their 2nd line treatment.
Interestingly, EGFR mutations were detected only in the
biopsy in 11 patients or only in the plasma in 6 patients.
The results could reflect the sensitivity limitation of
allele-specific PCR or biological differences in blood
when patients progressed from first-line chemotherapy.
A mutation found only in the diagnostic biopsy but not
in plasma removed several months later may reflect the
disappearance of the mutated cells, and an investigation
of biopsies and plasma samples taken at the same time
could elucidate this. Most of our patients (78%) were
primarily treated with conventional chemotherapy and
radiotherapy until progression and then erlotinib treat-
ment was started. Currently, it is unknown whether
biomarker status changes after exposure to chemother-
apy or on progression, but a recent study by Bai et al.
demonstrates that chemotherapy might reduce EGFR
mutation frequency in both plasma and biopsy samples
[5]. That insufficient mutated DNA is released to the
plasma to allow detection is another possibility in patients
with mutations in biopsies but not in plasma. Also, theof patients with (green line) or without (blue line) activating
g EGFR mutations has a significantly longer PFS than the group
Weber et al. BMC Cancer 2014, 14:294 Page 5 of 6
http://www.biomedcentral.com/1471-2407/14/294occurrence of mutated DNA in plasma despite a wild-type
result in the diagnostic biopsy is of interest. This may
reflect the appearance of mutated cells between the taking
of the diagnostic biopsy and the plasma sample but may
also reflect the presence of mutated metastases not
reflected in the diagnostic biopsy. Another explanation
could be that some tumours contain several clones of
which only some contain mutations in the EGFR gene
and that the biopsy was taken in a clone without EGFR
mutation. So far the therapeutic consequences of muta-
tions present only in the plasma remain unknown, and
the seven patients identified in this study are too few to
allow us to analyse this question.
In our study, we demonstrated that patients with activat-
ing EGFR mutations in plasma DNA have a significantly
longer progression-free survival than observed in the group
without these mutations, with a median progression-free
survival of 5.7 vs. 2.8 months, respectively. This suggests
that mutation detection in plasma DNA has clinical utility,
but larger studies are required to clarify this.
Previous studies have compared the presence of mutated
EGFR in plasma and in biopsies. These studies are all rela-
tively small, and comparisons are hampered by variation in
design, use of either plasma or serum, and in differences in
methods used for the detection of EGFR mutations
[5-9,11,12]. The concordance between EGFR status in
tumour and plasma/serum samples varies from 58% to
93% in these studies. This variance might be explained
by different sensitivities of the methods used. Most of
these studies were retrospective and based on only a
few selected patients. In the IPASS study, serum and
tissue samples were collected before any therapy, but
the concordance was only 66% [8]. A recent study found a
concordance rate between tumour and serum DNA of
92%, but this study was based on only 22 patients [12].
Thus, the concordance of 91% in our large cohort of
unselected patients is high compared to other studies.
A discordance of EGFR mutations in primary tumours
and corresponding metastases has been reported [13] as
well as intratumoural heterogeneity. Only a few studies
have investigated the influence of this heterogeneity on
treatment response, but a recent study suggests that the
mutation status in the metastasis has a high impact on
treatment outcome [13]. Even though this heterogeneity
is known in many cancers and especially in NSCLC, a
clinical decision is often based on only one biopsy. As
the blood mirrors the entire tumour burden, the use of
plasma DNA for EGFR mutation might be more precise
and informative. It is well known that mutations causing
TKI resistance that cannot be detected in the pre-
treatment specimen in patients responding to TKIs may
be detected later when the patients relapse [10]. Tumour
genotyping by using plasma DNA isolated immediately
before and during treatment may therefore be moreinformative than tumour genotyping of the diagnostic
biopsy and may prove useful to monitor therapy response
and/or disease progression.
Conclusion
We demonstrated the feasibility of measuring EGFR mu-
tations in plasma. Our results warrant further studies in
order to clarify whether plasma can replace biopsies for
the detection of EGFR mutations and to what extent serial
measurements of mutations in plasma may help the clin-
ician in choosing the optimal therapy for the patient.
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